Femara (Letrozole 2.5 mg | 30 Tabs)
Effective Treatment for Hormone Receptor-Positive Breast Cancer
🧬 What is Femara?
Femara (Letrozole) is a highly effective medication used for the treatment of breast cancer in postmenopausal women. It works by reducing estrogen levels in the body, which can help slow or stop the growth of hormone receptor-positive breast cancer cells.
Femara is commonly used in both early-stage and advanced breast cancer treatment, including as an adjuvant therapy for postmenopausal women who have undergone other forms of breast cancer treatment.
🩺 Indications for Use
Femara is prescribed for the following medical conditions:
1. Adjuvant Treatment of Early Breast Cancer
-
Postmenopausal women with hormone receptor-positive early breast cancer.
2. Extended Adjuvant Treatment of Early Breast Cancer
-
Postmenopausal women who have already undergone 5 years of adjuvant tamoxifen therapy.
3. First and Second-Line Treatment of Advanced Breast Cancer
-
For postmenopausal women with hormone receptor-positive or unknown locally advanced or metastatic breast cancer.
-
Also indicated for patients with disease progression following antiestrogen therapy.
⚖️ Dosage and Administration
The recommended dose of Femara is 2.5 mg per tablet, taken once daily, with or without food.
For Early Breast Cancer:
-
Optimal duration of treatment is not known, but treatment typically lasts around 5 years before discontinuation upon relapse.
For Extended Adjuvant Treatment:
-
Typically continued for 5 years, with 71% of patients treated for at least 3 years, and 58% completing at least 4.5 years of treatment.
For Advanced Breast Cancer:
-
Treatment continues until tumor progression is evident.
In Hepatic Impairment:
-
No dosage adjustment is necessary for mild to moderate hepatic impairment.
-
For severe hepatic dysfunction, the dose should be reduced by 50% (administered every other day).
In Renal Impairment:
-
No dosage adjustment required for patients with creatinine clearance ≥ 10 mL/min.
💡 Key Benefits of Femara
-
Reduces Estrogen Production – Inhibits estrogen production to slow or stop the growth of estrogen-dependent cancer cells.
-
Adjuvant Therapy – Recommended after surgery for early-stage breast cancer to reduce the risk of recurrence.
-
Improves Disease-Free Survival (DFS) – Proven to improve disease-free survival rates for postmenopausal women with breast cancer.
-
Well-Tolerated – Suitable for long-term use with minimal side effects when monitored.
⚠️ Precautions and Side Effects
While Femara is generally well-tolerated, it is important to be aware of potential side effects, including:
-
Hot flashes
-
Joint pain
-
Fatigue
-
Nausea
-
Bone thinning (osteoporosis)
Consult your healthcare provider if you experience any severe side effects or if you have liver or kidney problems.
💊 Product Details
-
Active Ingredient: Letrozole (2.5 mg per tablet)
-
Pack Size: 30 tablets
-
Formulation: Oral tablets, dark yellow, film-coated, round, slightly biconvex
-
Imprint: FV on one side, CG on the other side
-
Storage: Store at room temperature, away from moisture, and out of reach of children.
✅ Conclusion
Femara (Letrozole 2.5 mg) is a clinically proven treatment for breast cancer in postmenopausal women, effectively lowering estrogen levels to slow or prevent cancer growth. Whether used in early-stage, extended adjuvant, or advanced cancer, Femara plays a critical role in improving survival rates and preventing recurrence. Consult your doctor to determine if Femara is suitable for your treatment plan.
Reviews
There are no reviews yet.